"
Team:UCSF
From 2010.igem.org
Crystalliu (Talk | contribs) |
Crystalliu (Talk | contribs) |
||
| Line 17: | Line 17: | ||
{| style="color:white;background-color:#FF9900;" cellpadding="3" cellspacing="2" border="0" bordercolor="#fff" width="94%" align="center" | {| style="color:white;background-color:#FF9900;" cellpadding="3" cellspacing="2" border="0" bordercolor="#fff" width="94%" align="center" | ||
!align="center"|[[Team:UCSF|Home]] | !align="center"|[[Team:UCSF|Home]] | ||
| - | |||
!align="center"|[[Team:UCSF/Team|Team]] | !align="center"|[[Team:UCSF/Team|Team]] | ||
!align="center"|[https://igem.org/Team.cgi?year=2010&team_name=UCSF Official Team Profile] | !align="center"|[https://igem.org/Team.cgi?year=2010&team_name=UCSF Official Team Profile] | ||
Revision as of 17:27, 18 August 2010
| Home | Team | Official Team Profile | Project | Parts Submitted to the Registry | Modeling | Notebook | Safety |
|---|
Project Description
Natural killer (NK) cells of the immune system identify cancer and virally-infected cells and kill them. These potent killers travel throughout the body, recognizing proteins and other molecules on the surface of cells. In order to differentiate between healthy and diseased cells, NK cells use a variety of receptors, which bind to specific ligands at the target cells’ surface. The balance between activating and inhibitory signals will tell the NK cell if the target cell is diseased or healthy, respectively. If the target cell is deemed potentially dangerous, the NK cell grips the target cell tightly and creates an immunological synapse at the site of adhesion. Within this immunological synapse, the NK cell releases cytotoxic granules to kill the target cell without harming any nearby cells allowing for a direct, apoptotic death.
Our team will focus on improving NK cells’ specificity and killing efficiency towards certain cancer types. By using synthetic biology tools and logic gates’ design, we hope to create powerful killing biomachines for the fight against cancer. Our newly engineered synthetic devices would have the potential to enhance current adoptive cell-based immunotherapy for cancer patients.
